Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2019)

Vir Biotechnology (VIR) reported Gains from Investment Securities of -$1.4 million for Q4 2019, up 22.96% on a YoY basis from -$1.1 million in Q4 2018, and down 151.66% sequentially from $2.6 million in Q3 2019.

Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2019) Analysis & Trends

Vir Biotechnology (VIR) has 2 years of Gains from Investment Securities data on file, last reported at -$1.4 million in Q4 2019.

  • For the quarter ending Q4 2019, Gains from Investment Securities rose 22.96% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2019 stood at $2.0 million (changed N/A YoY), and the FY2023 full-year result was $1.0 million, down 51.58% from the prior year.
  • Gains from Investment Securities retreated to -$1.4 million in Q4 2019, from $2.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.6 million in Q3 2019 to a low of -$1.8 million in Q4 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Vir Biotechnology 1.31 Bn 1.31 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2019 -1.35 Mn
Dec 31, 2019 -1.35 Mn
Sep 30, 2019 2.62 Mn
Sep 30, 2019 2.62 Mn
Jun 30, 2019 427,000.00
Jun 30, 2019 427,000.00
Mar 31, 2019 357,000.00
Mar 31, 2019 357,000.00
Dec 31, 2018 -1.76 Mn
Dec 31, 2018 -1.76 Mn